NexImmune, Inc.

OTCPK:NEXI Stock Report

Market Cap: US$139.0

NexImmune Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on NexImmune's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Analysis Article • Sep 07

NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Aug 15

Neximmune GAAP EPS of -$0.69 misses by $0.01

Neximmune press release (NASDAQ:NEXI): Q2 GAAP EPS of -$0.69 misses by $0.01. Shares +3.2% AH. Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) submission for NEXI-003, the Company’s first solid tumor product candidate for the treatment of HPV-related cancers Plans to report additional preclinical and IND enabling data for the AIM Injectable platform in 2H22 Clinical updates for the Company’s two lead product candidates in Phase 1/2 clinical trials expected in 4Q22 Company is prioritizing resources to support Company’s lead product candidates, NEXI-001 and NEXI-003
Seeking Alpha • Jul 14

NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers

NexImmune (NASDAQ:NEXI) stock jumped 23% postmarket on Thursday after the firm received investigational new drug clearance by FDA for its first cellular therapy candidate for solid tumors. NEXI-003, an autologous antigen-specific T cell product, is being developed for patients with relapsed or refractory HPV-related cancers. The IND clearance allows NEXI to begin phase 1 clinical trial to evaluate NEXI-003 for treatment of HPV-related cancers. The proposed study is a 2-part, multicenter, open-label, dose-finding, first-in-human study to evaluate safety and clinical activity of NEXI-003. "The dose escalation phase will consist of multiple safety cohorts investigating increasing doses of NEXI-003 followed by an expansion phase that will enroll 24-36 patients overall," NEXI said in a statement. After initial data and recommended phase 2 dose has been confirmed, NEXI plans to expand the NEXI-003 development program to include other HPV-related cancers and evaluate potential SOC combination options. NEXI stock has fallen 69% YTD.
Seeking Alpha • May 31

NexImmune: Selling For Under Cash Value

Shares of immune biopharma NexImmune have cratered 90% from their IPO pricing as early returns from two Phase 1/2 trials have failed to impress. In theory, the output from its AIM platform should improve upon CAR T therapies, as they are more specific and thus should be more effective and less toxic. Trading at a discount to cash, but with only enough to get NexImmune to 2Q23 (covering two data updates in 2H22), the recent purchases by three insiders merited further investigation. A full investment analysis follows in the paragraphs below.
Analysis Article • May 26

Here's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Dec 19

We're Keeping An Eye On NexImmune's (NASDAQ:NEXI) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Revenue & Expenses Breakdown

How NexImmune makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:NEXI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-21116
31 Mar 240-261111
31 Dec 230-321316
30 Sep 230-441430
30 Jun 230-491435
31 Mar 230-571542
31 Dec 220-631647
30 Sep 220-611645
30 Jun 220-611646
31 Mar 220-571642
31 Dec 210-511637
30 Sep 210-451530
30 Jun 210-391423
31 Mar 210-351219
31 Dec 200-331018
30 Sep 200-30917
31 Dec 190-23615

Quality Earnings: Insufficient data to determine if NEXI has high quality earnings.

Growing Profit Margin: Insufficient data to determine if NEXI's profit margins have improved over the past year.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if NEXI's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare NEXI's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if NEXI's earnings growth over the past year exceeded the Biotechs industry average.

Return on Equity

High ROE: NEXI has a negative Return on Equity (0%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/31 21:28
End of Day Share Price 2026/05/29 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NexImmune, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Kaveri PohlmanBTIG
Alethia YoungCantor Fitzgerald & Co.